肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

恶性肿瘤患者膳食指导 2018

2018-02-01 中华人民共和国国家卫生健康委员会 国家卫健委

肿瘤营养

恶性肿瘤患者膳食指导 2018

中文标题：

恶性肿瘤患者膳食指导 2018

发布机构：

中华人民共和国国家卫生健康委员会

发布日期：

2018-02-01

简要介绍：

标准号 WS/T 559—2017 标准名 恶性肿瘤患者膳食指导
发布时间 2017-08-01 实施时间 2018-02-01

相关资料下载：
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=02f631c00205a37d, title=恶性肿瘤患者膳食指导 2018, enTitle=, guiderFrom=国家卫健委, authorId=0, author=, summary=恶性肿瘤患者膳食指导 2018, cover=, journalId=0, articlesId=null, associationId=1653, associationName=中华人民共和国国家卫生健康委员会, associationIntro=, copyright=0, guiderPublishedTime=Thu Feb 01 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<table class="mt20 mb20" style="color: #222222;" border="1" width="100%" cellspacing="0" cellpadding="0" align="center"> <tbody style="color: #222222;"> <tr style="color: #222222;"> <td class="xxgk_td_bgcolor" style="color: #333333;" valign="top" nowrap="nowrap">标准号</td> <td class="zhupei" style="color: #333333;" valign="top">WS/T 559&mdash;2017</td> <td class="xxgk_td_bgcolor" style="color: #333333;" valign="top" nowrap="nowrap">标准名</td> <td style="color: #333333;" valign="top">恶性肿瘤患者膳食指导</td> </tr> <tr style="color: #222222;"> <td class="xxgk_td_bgcolor" style="color: #333333;" valign="top" nowrap="nowrap">发布时间</td> <td style="color: #333333;" valign="top">2017-08-01</td> <td class="xxgk_td_bgcolor" style="color: #333333;" valign="top" nowrap="nowrap">实施时间</td> <td style="color: #333333;" valign="top">2018-02-01</td> </tr> </tbody> </table>, tagList=[TagDto(tagId=119, tagName=肿瘤), TagDto(tagId=1821, tagName=营养)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=34, categoryName=全科与营养, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9956, appHits=327, showAppHits=0, pcHits=478, showPcHits=9628, likes=2, shares=24, comments=19, approvalStatus=1, publishedTime=Fri Feb 12 18:49:32 CST 2021, publishedTimeString=2018-02-01, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Fri Feb 12 18:49:29 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Thu Jan 04 21:00:07 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击：
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1055044, encodeId=50751055044e1, content=增加积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2c35412579, createdName=ms3000002077419869, createdTime=Sun Sep 26 17:23:38 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008688, encodeId=a7ec100868851, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:00:53 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964129, encodeId=d1cc964129ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3421424134, createdName=872286653, createdTime=Sun May 09 23:25:47 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961170, encodeId=a2619611e07a, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210128/d719c5a457e640d88a16efd137890639/57d598105aeb4783b9073e2f13733562.jpg, createdBy=73dc5434031, createdName=ms3000000503829460, createdTime=Wed Apr 28 10:52:10 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959592, encodeId=1a9e959592e3, content=药补不如食补, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf5474917, createdName=ms6000000798860771, createdTime=Thu Apr 22 21:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=)]
    2021-09-26 ms3000002077419869

    增加积分

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1055044, encodeId=50751055044e1, content=增加积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2c35412579, createdName=ms3000002077419869, createdTime=Sun Sep 26 17:23:38 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008688, encodeId=a7ec100868851, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:00:53 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964129, encodeId=d1cc964129ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3421424134, createdName=872286653, createdTime=Sun May 09 23:25:47 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961170, encodeId=a2619611e07a, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210128/d719c5a457e640d88a16efd137890639/57d598105aeb4783b9073e2f13733562.jpg, createdBy=73dc5434031, createdName=ms3000000503829460, createdTime=Wed Apr 28 10:52:10 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959592, encodeId=1a9e959592e3, content=药补不如食补, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf5474917, createdName=ms6000000798860771, createdTime=Thu Apr 22 21:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=)]
    2021-08-17 ms1000001256854968

    赞赞赞

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1055044, encodeId=50751055044e1, content=增加积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2c35412579, createdName=ms3000002077419869, createdTime=Sun Sep 26 17:23:38 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008688, encodeId=a7ec100868851, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:00:53 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964129, encodeId=d1cc964129ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3421424134, createdName=872286653, createdTime=Sun May 09 23:25:47 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961170, encodeId=a2619611e07a, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210128/d719c5a457e640d88a16efd137890639/57d598105aeb4783b9073e2f13733562.jpg, createdBy=73dc5434031, createdName=ms3000000503829460, createdTime=Wed Apr 28 10:52:10 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959592, encodeId=1a9e959592e3, content=药补不如食补, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf5474917, createdName=ms6000000798860771, createdTime=Thu Apr 22 21:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=)]
    2021-05-09 872286653

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1055044, encodeId=50751055044e1, content=增加积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2c35412579, createdName=ms3000002077419869, createdTime=Sun Sep 26 17:23:38 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008688, encodeId=a7ec100868851, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:00:53 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964129, encodeId=d1cc964129ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3421424134, createdName=872286653, createdTime=Sun May 09 23:25:47 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961170, encodeId=a2619611e07a, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210128/d719c5a457e640d88a16efd137890639/57d598105aeb4783b9073e2f13733562.jpg, createdBy=73dc5434031, createdName=ms3000000503829460, createdTime=Wed Apr 28 10:52:10 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959592, encodeId=1a9e959592e3, content=药补不如食补, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf5474917, createdName=ms6000000798860771, createdTime=Thu Apr 22 21:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=)]
    2021-04-28 ms3000000503829460

    点赞

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1055044, encodeId=50751055044e1, content=增加积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2c35412579, createdName=ms3000002077419869, createdTime=Sun Sep 26 17:23:38 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008688, encodeId=a7ec100868851, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:00:53 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964129, encodeId=d1cc964129ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3421424134, createdName=872286653, createdTime=Sun May 09 23:25:47 CST 2021, time=2021-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961170, encodeId=a2619611e07a, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210128/d719c5a457e640d88a16efd137890639/57d598105aeb4783b9073e2f13733562.jpg, createdBy=73dc5434031, createdName=ms3000000503829460, createdTime=Wed Apr 28 10:52:10 CST 2021, time=2021-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959592, encodeId=1a9e959592e3, content=药补不如食补, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf5474917, createdName=ms6000000798860771, createdTime=Thu Apr 22 21:44:57 CST 2021, time=2021-04-22, status=1, ipAttribution=)]
    2021-04-22 ms6000000798860771

    药补不如食补

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

抗肿瘤药临床试验影像评估程序标准技术指导原则(2021年）

国家药品监督管理局药品审评中心（CDE） · 2021-01-14

抗肿瘤药物临床试验统计学设计指导原则（试行）（2020年）

国家药品监督管理局药品审评中心（CDE） · 2020-12-31

抗肿瘤药联合治疗临床试验技术指导原则（2020年）

国家药品监督管理局药品审评中心（CDE） · 2020-12-30

抗肿瘤创新药上市申请安全性总结资料准备技术指导原则（2020年）

国家药品监督管理局药品审评中心（CDE） · 2020-12-30

新型抗肿瘤药物临床应用指导原则(2020年版)

中华人民共和国国家卫生健康委员会 · 2020-12-29

抗肿瘤药物临床应用管理办法(试行)

中华人民共和国国家卫生健康委员会 · 2020-12-22